Psilocybin and Lyme Disease?

Psilocybin is both serotonergic and anti-inflammatory and therefore may offer significant therapeutic benefits to patients with mental illness secondary to autoimmune inflammation.

This study suggests that the role of microdosed psilocybin in the treatment of neuropsychiatric Lyme disease and autoimmune encephalopathies warrants further study.

Read more

Update on Oregon

In 2020, Oregon was the first state in the U.S. to effectively legalize psilocybin, the hallucinogenic component of magic mushrooms, for therapeutic use.

It has shown to be effective in treating post-traumatic stress disorder, depression and end-of-life anxiety.

Since then, regulations and restrictions for psilocybin treatment have taken shape across the state with many rural counties opting out of providing any psilocybin-related services at all.

Read more

Global Survey 2020 Results: Self-Treatment of LSD and Psilocybin

The Global Drug Survey 2020 is a large online survey on drug use collected between November 2019 and February 2020.

Positive changes were observed across all 17 outcome items, with the strongest benefits on items related to insight and mood. Negative effects were reported by 22.5% of respondents.

High intensity of psychedelic experience, seeking advice before treatment, treating with psilocybin mushrooms and treating post-traumatic stress disorder were associated with higher scores on the self-treatment outcome scale after averaging values across all 17 items.

Younger age, high intensity of experience and treating with LSD were associated with increased number of negative outcomes.

Read more

Recent Research on Psilocybin Gives Mixed Results

Compass Pathways published the long awaited results of its phase 2 clinical trial for the treatment of depression with psilocybin–assisted psychotherapy in the New England Journal of Medicine.

Psilocybin showed rapid antidepressant effects for most patients, but only 1 in 5 participants showed significant improvement at 12 weeks.

Read more